Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

Open access
Oakes, Samantha R., Vaillant, François, Lim, Elgene, Lee, Lily, Breslin, Kelsey, Feleppa, Frank, Deb, Siddhartha, Ritchie, Matthew E., Takano, Elena, Ward, Teresa, Fox, Stephen B., Generali, Daniele, Smyth, Gordon K., Strasser, Andreas, Huang, David C. S., Visvader, Jane E., Lindeman, Geoffrey J.·2012·Proceedings of the National Academy of Sciences

Abstract

Overexpression of the prosurvival protein BCL-2 is common in breast cancer. Here we have explored its role as a potential therapeutic target in this disease. BCL-2, its anti-apoptotic relatives MCL-1 and BCL-XL, and the proapoptotic BH3-only ligand BIM were found to be coexpressed at relatively high levels in a substantial proportion of heterogeneous breast tumors, including clinically aggressive basal-like cancers. To determine whether the BH3 mimetic ABT-737 that neutralizes BCL-2, BCL-XL, and BCL-W had potential efficacy in targeting BCL-2–expressing basal-like triple-negative tumors, we generated a panel of primary breast tumor xenografts in immunocompromised mice and treated recipients with either ABT-737, docetaxel, or a combination. Tumor response and overall survival were significantly improved by combination therapy, but only for tumor xenografts that expressed elevated levels of BCL-2. Treatment with ABT-737 alone was ineffective, suggesting that ABT-737 sensitizes the tumor cells to docetaxel. Combination therapy was accompanied by a marked increase in apoptosis and dissociation of BIM from BCL-2. Notably, BH3 mimetics also appeared effective in BCL-2–expressing xenograft lines that harbored p53 mutations. Our findings provide in vivo evidence that BH3 mimetics can be used to sensitize primary breast tumors to chemotherapy and further suggest that elevated BCL-2 expression constitutes a predictive response marker in breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1104778108

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 193

Metadata

Authors
Oakes, S. R., Vaillant, F., Lim, E., Lee, L., Breslin, K., Feleppa, F., Deb, S., Ritchie, M. E., Takano, E., Ward, T., Fox, S. B., Generali, D., Smyth, G. K., Strasser, A., Huang, D. C. S., Visvader, J. E., & Lindeman, G. J.
Venue
Proceedings of the National Academy of Sciences
Published
2011-07-18
Volume
109
Issue
8
Pages
2766-2771
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2098842169
Cited by
193
References
4
FWCI
4.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. https://app.cochat.ai/papers/10.1073/pnas.1104778108
The paper
Oakes, S. R., Vaillant, F., Lim, E., Lee, L., Breslin, K., Feleppa, F., Deb, S., Ritchie, M. E., Takano, E., Ward, T., Fox, S. B., Generali, D., Smyth, G. K., Strasser, A., Huang, D. C. S., Visvader, J. E., & Lindeman, G. J. (2012). Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1104778108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.